The 19 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 84.00, with a high estimate of 135.00 and a low estimate of 42.00. The median estimate represents a +256.23% increase from the last price of 23.58.
The current consensus among 20 polled investment analysts is to Buy stock in Fate Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.83
Reporting Date Aug 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.